img Not actual patient.
LET’S TALK ABOUT

PATIENTS LIKE SARAH

A patient with type 1 diabetes struggling to maintain glycemic control

On basal insulin and injects insulin aspart before meals

Has an A1C of 8.2 and is concerned about hypoglycemia

Tired of scheduling meals around injections

Anxious about frequency of continuous glucose monitor (CGM) alerts

CGM

Makes Sarah
realize she’s not
maintaining control

GIVE PATIENTS LIKE SARAH IMPROVED MEALTIME CONTROL WITH AFREZZA® 1,2,7

  • Afrezza delivers an ultra-rapid insulin response with absorption in the blood in <1 minute1,4
  • Time to first measurable effect is ~12 minutes1
  • Patients inhale Afrezza at mealtime, when they are ready to eat, with no needlesticks1
  • Afrezza was proven to be non-inferior to subcutanous (SC) rapid-acting insulin in
    clinical trials1,7
img Not actual patient.
TYPE1

Patient Profile:Sarah

Drag & Drop:What features of an inhaled insulin might help a patient like Sarah?

Drag the items to sort them in the order of importance to you, with 1 being the most important

Rapid insulin response1,4
Proven mealtime control1,7
Safety profile1
Flexible and convenient dosing1
1234
img

Sarah’s
Journey

Your
ranking

LET’S TALK ABOUT

MEALTIME CONTROL

Afrezza® delivers a rapid insulin response for significant improvements in mealtime glycemic control2

TYPE1

POSTPRANDIAL GLUCOSE (PPG) LEVELS OVER 4 HOURS VS SC RAPID-ACTING COMPARATOR2

img
img

Study design:Afrezza efficacy was studied in a pilot, investigator-led, open label, multicenter trial of 60 patients with t1dm with A1C levels ≥6.5% and ≤10%. Individuals were randomized to treatment with Afrezza (n=26) or subcutaneous (SC) rapid-acting insulin (n=34). All were required to wear a real-time CGM throughout the trial.2

img

Sarah’s
Journey

Your
ranking

LET’S TALK ABOUT

MEALTIME CONTROL

Afrezza® delivers a rapid insulin response for significant improvements in mealtime glycemic control2

TYPE1

PPG EXCURSIONS 1-4 HOURS AFTER MEAL VS SC RAPID-ACTING COMPETITOR2

img
img

Study design:Afrezza efficacy was studied in a pilot, investigator-led, open label, multicenter trial of 60 patients with t1dm with A1C levels ≥6.5% and ≤10%. Individuals were randomized to treatment with Afrezza (n=26) or subcutaneous (SC) rapid-acting insulin (n=34). All were required to wear a real-time CGM throughout the trial.2

img

Sarah’s
Journey

Your
ranking

LET’S TALK ABOUT

THE SAFETY PROFILE

Afrezza® has been studied in over 3,000 patients with diabetes1

TYPE1

MOST COMMON ADVERSE REACTIONS (ARs) IN PATIENTS WITH TYPE 1 DIABETES,
EXCLUDING HYPOGLYCEMIA1

img
img

Sarah’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION BY

CONSIDERING THE PATIENT

TYPE1

TOTAL HYPOGLYCEMIA AS A FUNCTION OF TIME IN THE TYPE 1 STUDY7

img

Study design:This open-label non-inferiority trial compared the change in A1C from baseline to week 24 of prandial Afrezza (n=174) with that of SC rapid-acting insulin (n=170), both with basal insulin,
in adult patients (≥18 years) with type 1 diabetes and A1C of 7.5% to 10%.

Afrezza provided less A1C reduction than SC rapid-acting insulin,
and the difference was statistically significant. More subjects in the SC rapid-acting insulin group achieved the A1C target of ≤7%.7

img

Sarah’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION WITH

PROVEN CONTROL

Switching to Afrezza® maintained acceptable glucose control1,7

TYPE1

MEAN A1C LEVELS OVER 24-WEEK TREATMENT PERIOD1,7

img
img

Data from an open-label non-inferiority trial compared the change in A1C from baseline to week 24 of prandial Afrezza (n=174) with that of SC rapid-acting insulin (n=170), both with basal insulin, in adult patients (≥18 years) with type 1 diabetes and A1C of 7.5% to 10%. Afrezza provided less A1C reduction than rapid-acting insulin, and the difference was statistically significant. More subjects in the SC rapid-acting group achieved the A1C target of ≤7%.7

img

Sarah’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION WITH

PROVEN CONTROL

Switching to Afrezza® delivered significantly more time-in-range2

MEALTIME SUPPLEMENT AT
1 AND/OR 2 HOURS POST-MEAL2

img

TIME-IN-RANGE (TIR)2

img
img

Data from a pilot, investigator-led, open-label, multicenter trial of 60 patients with t1dm with A1C levels ≥6.5% and ≤10%. Individuals were randomized to treatment with titrated Afrezza (n=26) or titrated SC rapid-acting insulin (n=34). All were required to wear a real-time CGM throughout the trial.2

img

Sarah’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION ABOUT

DOSING + TITRATION

Afrezza® mealtime control is possible with flexible dosing1

4, 8 & 12 Units

Available Afrezza cartridge options1

1.5x

Conversation from injectable insulin to Afrezza units for comfortable effect7,8,9

Adjust Dosing

As needed to achieve optimal control1

This Afrezza Titration Pack offers flexibility for patients getting started:

img

Sarah’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION ABOUT

DOSING + TITRATION

Afrezza® mealtime control is possible with flexible dosing1

INITIAL INSULIN DOSE
CONVERSION + TITRATION DOSE1

img
img
REFERENCES
  • Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation.
  • Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther. 2018;20(10):639–647.
  • Lasalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(3):152–162.
  • Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):205–212.
  • Rossetti P, Porcellati F. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(2):S113–S120.
  • Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245.
  • Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38(12):2266–2273.
  • Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naive subjects with type 2 diabetes inadequately controlled on oral antidiabetes agent. Diabetes Care. 2015;38(12):2274–2281.
  • Data on file. MannKind Corporation.
  • Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244–2253.
  • Riddle MC. Basal glucose can be controlled, but the prandial problem persists–it’s the next target! Diabetes Care. 2017;40(3):291-300.
  • Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11)3411-3417.
  • Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6(4):773-779.
img
TYPE2

Would you like to review

jason’s patient profile?

Yes, pleaseNo, thank you
img
img
TYPE1

Would you like to review

SARAH’s patient profile?

Yes, pleaseNo, thank you
img